Medical News

RSS

Harbor BioSciences reports encouraging results from Triolex Phase IIa trials

Harbor Biosciences, a biopharmaceutical company developing novel therapeutics for the treatment of cancer, metabolic and inflammatory diseases, today released an update to its development program for Triolex to treat obesity-induced insulin resistance and type-2 diabetes mellitus (T2DM).

10 May 2010

Endosense commences enrollment in EFFICAS I study with TactiCath force-sensing catheter

Endosense, a Swiss medical technology company focused on improving the efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias, has announced it has enrolled the first patients in EFFICAS I, the first study of the EFFICAS series. These patients were enrolled in Na Homolce Hospital, Prague, Czech Republic and treated by Petr Neuzil, M.D. and Vivek Reddy, M.D.

10 May 2010

Asthmatx announces first U.S. patient treated with BT delivered by Alair System

Asthmatx, Inc. reported today that doctors at Virginia Hospital Center in Arlington, Va., recently treated the first U.S. patient with bronchial thermoplasty (BT) delivered by the Alair® System, the first device-based asthma treatment approved by the U.S. Food and Drug Administration (FDA).

10 May 2010

CFMG to adopt eClinicalWorks EMR system

eClinicalWorks®, a market leader in ambulatory clinical systems, today announced that California Forensic Medical Group (CFMG), which provides health care to correctional facilities in 25 counties in the state, has selected eClinicalWorks electronic medical records (EMR) system. Using eClinicalWorks will allow the group to streamline operations and improve the quality of care provided through reporting capabilities and the ability to share data across the counties. This will help in the continuity of care for inmates.

10 May 2010

Bovie Medical first-quarter revenues decrease to $5.6M

Bovie Medical Corporation, a manufacturer and marketer of electrosurgical products, today announced its financial results for the first quarter ended March 31, 2010.

10 May 2010

Health Canada approves BDSI's NDS for ONSOLIS

BioDelivery Sciences International, Inc. today announced the approval of a New Drug Submission (NDS) by Health Canada, the regulatory authority in Canada, for ONSOLIS (fentanyl buccal soluble film) in the management of breakthrough pain in opioid-tolerant adult patients with cancer. ONSOLIS is the first product approved in Canada for this indication.

10 May 2010

Immunomedics third-quarter revenues increase to $10.7 million

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported financial results for the third quarter ended March 31, 2010. The Company also highlighted recent key developments and planned activities for its clinical pipeline.

10 May 2010

Ferring to acquire global rights to Xanodyne Pharmaceutical's LYSTEDA

Ferring Pharmaceuticals today announced an agreement that will expand its Women's Health product portfolio with the acquisition of the global rights to Xanodyne Pharmaceutical's LYSTEDA™ (tranexamic acid), a first-in-class, non-hormonal therapy indicated specifically for treatment of women with cyclic heavy menstrual bleeding (HMB).

10 May 2010

St. Jude Medical introduces Wireless USB Adaptor for Merlin@home transmitter in the U.S.

St. Jude Medical, Inc., a global medical device company, today announced the U.S. launch of its Wireless USB Adaptor for the Merlin@home™ transmitter, a system that allows important patient data from an implantable cardiac device to be wirelessly downloaded and securely transmitted via telephone for review by a physician. The new Wireless USB Adaptor enables patients using a Merlin@home transmitter to transmit data to their physician over cellular networks, allowing for more convenient care than existing landline services provide.

10 May 2010

NHI first-quarter normalized FFO increases to $17.17M, net income to $15.94M

National Health Investors, Inc. announced today its normalized Funds From Operations ("FFO") and net income for the three months ended March 31, 2010.

10 May 2010

Total kidney removal not beneficial for elderly patients with confined kidney tumors

A new study indicates that patients aged 75 years or older who have confined kidney tumors do not live longer if they have their entire kidney removed. The research reveals that these patients typically have other medical problems of greater significance and that many should receive more conservative cancer-related care, such as observation or treatments that spare the noncancerous parts of their kidneys. The study is published early online in CANCER, a peer-reviewed journal of the American Cancer Society.

10 May 2010

Mice express pain through facial expressions, says study

A new study by researchers from McGill University and the University of British Columbia shows that mice, like humans, express pain through facial expressions.

10 May 2010

Watson Pharmaceuticals first-quarter net revenue up 28% to $856.5M

Watson Pharmaceuticals, Inc. today reported a 28 percent increase in net revenue for the first quarter ended March 31, 2010 to $856.5 million, compared to $667.4 million in the first quarter 2009. On an adjusted cash basis, net income increased 25 percent to $100.3 million or $0.81 per share, compared to $80.2 million or $0.69 per share in the first quarter 2009. GAAP earnings for the first quarter 2010 were $0.57 per share, compared to $0.43 per share in the prior year period.

10 May 2010

European patent strengthens Soligenix' topically active steroid intellectual property portfolio

Soligenix, Inc., a late-stage biotechnology company, announced today that the European Patent Office granted patent EP 1392321 "Method of Treating Inflammatory Disorders of the Gastrointestinal Tract using Topically Active Corticosteroids." The new patent's main claims cover the use of topically active corticosteroids in orally administered dosage forms that act concurrently in the upper and lower gastrointestinal tract.

10 May 2010

Astute Medical completes $26.5 million series B financing

Astute Medical, Inc., a developer of novel, biomarker-based medical diagnostics, today announced completion of a $26.5 million series B financing co-led by Domain Associates and Delphi Ventures. Astute will use the funding to advance research and development aimed at the identification and validation of protein biomarkers with the goal of commercializing high potential diagnostic products.

10 May 2010

Healing Arts Cooperative Medical Marijuana to open new location in San Diego

International Merchant Advisors, Inc. announced today that the company's client, Healing Arts Cooperative Medical Marijuana is opening a new location in San Diego. IMAI has previously signed a management agreement to operate all of the Healing Arts Cooperative Medical Marijuana dispensaries and to operate the cooperative as the manager of the facility on behalf of its non profit owners. Healing Arts is a cash flow generating non profit, fulfilling the needs of medical marijuana patients in California and planning further expansion in the state.

10 May 2010

Shamir first-quarter revenue up 18.2% to $40.1 million

Shamir Optical Industry Ltd., a leading provider of innovative products and technology to the ophthalmic lens market, today announced unaudited financial results for the first quarter ended March 31, 2010.

10 May 2010

Accuri Cytometers, eBioscience announce worldwide co-marketing agreement

Accuri Cytometers, Inc., the fastest growing life sciences company marketing and producing revolutionary bench-top flow cytometer systems, and eBioscience, the number two supplier of research flow cytometry reagents, today announced that they have entered into a worldwide co-marketing agreement.

10 May 2010

Achillion reports lower net loss of $5.6M for first-quarter 2010

Achillion Pharmaceuticals, Inc., a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported financial results for the three months ended March 31, 2010. For the first quarter of 2010, the Company reported a net loss of $5.6 million or $0.16 per share, compared with a net loss of $6.7 million or $0.25 per share for the first quarter of 2009. Cash, cash equivalents and marketable securities as of March 31, 2010 were $25.0 million, up $15.3 million compared with December 31, 2009.

10 May 2010

First Edition: May 10, 2010

Today's health policy headlines include the feature coverage of aspects of health reform implementation, including how "gradfathering" will be defined in regulations and the latest details on the early retiree reinsurance program.

10 May 2010